Compare Mutual Funds

Insights from Fund Comparison

• Both Nippon India Pharma Fund - Direct (G) and Nippon India Pharma Fund - Direct (Bonus) are Sectoral / Thematic, Equity schemes. Nippon India Pharma Fund - Direct (G) is 13 yrs 4 m old and manages ₹8,365.4 Crs, whereas Nippon India Pharma Fund - Direct (Bonus) is 13 yrs 4 m old with ₹8,365.4 Crs.
• Both funds are fairly comparable in terms of age and size.
• Nippon India Pharma Fund - Direct (G) has its top 3 sectors in Pharmaceuticals (73.12%), Healthcare (20.02%), and Retail (3.78%), while Nippon India Pharma Fund - Direct (Bonus) focuses on Pharmaceuticals (73.12%), Healthcare (20.02%), and Retail (3.78%).
• Both funds have identical top sector allocations, so sector-level performance will likely impact them similarly.
• Nippon India Pharma Fund - Direct (G) holds Sun Pharmaceutical Industries Limited (13.85%), Lupin Limited (7.95%), Dr. Reddy's Laboratories Limited (7.04%), Divi's Laboratories Limited (6.61%), and Cipla Limited (5.47%), whereas Nippon India Pharma Fund - Direct (Bonus) holds Sun Pharmaceutical Industries Limited (13.85%), Lupin Limited (7.95%), Dr. Reddy's Laboratories Limited (7.04%), Divi's Laboratories Limited (6.61%), and Cipla Limited (5.47%).
• Both funds share identical top holdings, meaning their performance will be very similar and primarily differ based on portfolio weight distribution.
• In terms of risk profile, Nippon India Pharma Fund - Direct (G) has 98.70% equity and 0.00% debt, while Nippon India Pharma Fund - Direct (Bonus) has 98.70% equity and 0.00% debt.
• Risk profile is similar for both funds.